Spectinomycin adverse reactions: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Spectinomycin}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TROBICIN (SPECTINOMYCIN) [PHARMACIA AND UPJOHN, CO.] | url =...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Adverse Reactions== | |||
The following reactions were observed during the single dose clinical trials: soreness at the injection site, urticaria, dizziness, nausea, chills, fever and insomnia. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TROBICIN (SPECTINOMYCIN) [PHARMACIA AND UPJOHN, CO.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=becf7b7a-508c-44ff-add0-558a60fd0067 | publisher = | date = | accessdate = }}</ref> | During multiple dose subchronic tolerance studies in normal human volunteers, the following were noted: a decrease in hemoglobin, hematocrit and creatinine clearance; elevation of alkaline phosphatase, BUN and SGPT. In single and multiple dose studies in normal volunteers, a reduction in urine output was noted. Extensive renal function studies demonstrated no consistent changes indicative of renal toxicity. | ||
A few cases of anaphylaxis or anaphylactoid reactions have been reported. If serious allergic reactions occur, the usual agents (epinephrine, corticosteroids, and/or antihistamines) should be available for emergency use. In cases of severe anaphylaxis, airway support and oxygen may also be required.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TROBICIN (SPECTINOMYCIN) [PHARMACIA AND UPJOHN, CO.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=becf7b7a-508c-44ff-add0-558a60fd0067 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 01:26, 24 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Adverse Reactions
The following reactions were observed during the single dose clinical trials: soreness at the injection site, urticaria, dizziness, nausea, chills, fever and insomnia.
During multiple dose subchronic tolerance studies in normal human volunteers, the following were noted: a decrease in hemoglobin, hematocrit and creatinine clearance; elevation of alkaline phosphatase, BUN and SGPT. In single and multiple dose studies in normal volunteers, a reduction in urine output was noted. Extensive renal function studies demonstrated no consistent changes indicative of renal toxicity.
A few cases of anaphylaxis or anaphylactoid reactions have been reported. If serious allergic reactions occur, the usual agents (epinephrine, corticosteroids, and/or antihistamines) should be available for emergency use. In cases of severe anaphylaxis, airway support and oxygen may also be required.[1]
References
Adapted from the FDA Package Insert.